Teva Pharmaceutical Industries Stock Forecast, Price & News

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

Is Teva Pharmaceutical Industries a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries or view top-rated stocks.

What stocks does MarketBeat like better than Teva Pharmaceutical Industries?

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 28,530,000 shares, a decrease of 14.2% from the July 29th total of 33,240,000 shares. Based on an average daily volume of 9,030,000 shares, the days-to-cover ratio is presently 3.2 days.
View Teva Pharmaceutical Industries' Short Interest.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings data on Wednesday, July, 28th. The company reported $0.59 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.55 by $0.04. The business earned $3.91 billion during the quarter, compared to analysts' expectations of $4.03 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 23.88% and a negative net margin of 23.98%.
View Teva Pharmaceutical Industries' earnings history.

How has Teva Pharmaceutical Industries' stock price been impacted by COVID-19?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 2.6% and is now trading at $9.24.
View which stocks have been most impacted by COVID-19.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided EPS guidance of $2.500-$2.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.450. The company issued revenue guidance of $16 billion-$16.40 billion, compared to the consensus revenue estimate of $16.55 billion.

What price target have analysts set for TEVA?

7 equities research analysts have issued 12 month price objectives for Teva Pharmaceutical Industries' stock. Their forecasts range from $10.00 to $14.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries or view top-rated stocks among Wall Street analysts.

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:

• Kåre Schultz, President, Chief Executive Officer & Director
• Eric Drapé, Executive Vice President-Global Operations
• Eli Kalif, Chief Financial Officer & Executive Vice President
• Hafrun Fridriksdottir, Executive VP-Global Research & Development
• Lori A. Queisser, Senior Vice President & Global Compliance Officer

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

Who are some of Teva Pharmaceutical Industries' key competitors?

Some companies that are related to Teva Pharmaceutical Industries include BeiGene (BGNE), Astellas Pharma (ALPMY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Genmab A/S (GMAB), Shiseido (SSDOY), Genmab A/S (GNMSF), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), UCB (UCBJF), Viatris (VTRS), Elanco Animal Health (ELAN) and BioMarin Pharmaceutical (BMRN).
View all of TEVA's competitors.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Jefferies Group LLC (0.00%), BlackRock Inc. (3.64%), State Street Corp (1.50%), Susquehanna International Group LLP (0.00%), Capital International Investors (0.92%) and Harel Insurance Investments & Financial Services Ltd. (0.91%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Michael James Mcclellan, Pharmaceutical Co Ltd Takeda, Richard Daniell and Rosemary A Crane.
View institutional ownership trends for Teva Pharmaceutical Industries.

Which major investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Capital International Investors, Caisse DE Depot ET Placement DU Quebec, BlackRock Inc., First Light Asset Management LLC, Squarepoint Ops LLC, Millennium Management LLC, and Archon Partners LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Teva Pharmaceutical Industries or view top insider-selling stocks.

Which major investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Legal & General Group Plc, Bank of Montreal Can, Credit Suisse AG, Citadel Advisors LLC, Susquehanna International Group LLP, Renaissance Technologies LLC, and Deutsche Bank AG.
View insider buying and selling activity for Teva Pharmaceutical Industries or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $9.24.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries has a market capitalization of $10.09 billion and generates $16.66 billion in revenue each year. The company earns $-3,990,000,000.00 in net income (profit) each year or $2.45 on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 37,736 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Where are Teva Pharmaceutical Industries' headquarters?

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at (723) 926-7267 or via email at [email protected].